26 September 2019 in Journal of Thrombosis and Haemostasis
TIThe Subcommittee On Plasma Coagulation Inhibitors
The Subcommittee On Plasma Coagulation Inhibitors
+1
1 June 2015 in Thrombosis Research
11 April 2019 in Haematologica
MMMaría Eugenia de la Morena-Barrio
María Eugenia de la Morena-Barrio
Pediatric thromboembolism (≤18 years) is very rare (0.07-0.14/10,000/year) but may be more prevalent in children with severe thrombophilia (protein C, protein S or antithrombin deficiency). The aim of this study was to define the prevalence and clinical characteristics of pediatric thrombosis in subjects with inherited antithrombin deficiency. Our observational retrospective multicentric study from two countries recruited 968 patients of any age from 441 unrelated families with genetically, biochemically and functionally characterized antithrombin deficiency. Seventy-three subjects (7.5%) developed thrombosis before 19 years of age. Two high risk periods for thrombosis were identified: adolescence (12-18 years, n=49) with thrombus localization (lower limb, deep venous thrombosis or pulmonary embolism) and triggering factors common to adults (oral contraceptives, surgery or pregnancy); and neonatal period (<30 days, n=15) with idiopathic thrombosis at unusual sites. The clinical evaluation of pediatric thrombosis in subjects with antithrombin deficiency revealed: i) a high prevalence of cerebral sinovenous thrombosis (n=13, 17.8%), mainly at young age (8 neonates and 4 children <6 years); ii) severe outcome with fatality in 6 cases (3 neonates, two of them homozygous for p.Leu131Phe). The majority of subjects (76.7%) carried quantitative type I deficiency. This retrospective analysis of the so far largest cohort of subjects with inherited antithrombin deficiency provides strong evidence for an increased risk of pediatric thrombosis associated with this thrombophilia (300-fold compared with the general population: 0.41%/year vs 0.0014%/year, respectively). Our results support testing for antithrombin deficiency in children of affected families, particularly in case of type I deficiency.
23 February 2022 in The Journal of Molecular Diagnostics
BMBelén de la Morena-Barrio
Belén de la Morena-Barrio
+13
19 March 2021 in European Journal of Clinical Investigation
Click on the article title to read more.
3 October 2020 in Acta Clinica Belgica
COVID-19 predisposes patients to thrombotic disease. The aim of this guidance document is to provide Belgian health-care workers with recommendations on anticoagulation management in COVID-19 posit...